Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours
Open Access
- 26 May 2021
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 125 (4) , 520-527
Abstract
Background: Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We assessed the safety, tolerability, pharmacokinetics, and preliminary efficacy of berzosertib plus cisplatin.Methods: Adult patients with advanced solid tumours refractory or resistant to standard of care therapies received ascending doses of cisplatin (day 1) and berzosertib (days 2 and 9) every 3 weeks (Q3W).Results: Thirty-one patients received berzosertib (90–210 mg/m2) and cisplatin (40–75 mg/m2) across seven dose levels. The most common grade ≥3 treatment-emergent adverse events were neutropenia (20.0%) and anaemia (16.7%). There were two dose-limiting toxicities: a grade 3 hypersensitivity reaction and a grade 3 increase in alanine aminotransferase. Berzosertib 140 mg/m2(days 2 and 9) and cisplatin 75 mg/m2(day 1) Q3W was determined as the recommended Phase 2 dose. Cisplatin had no apparent effect on berzosertib pharmacokinetics. Of the 31 patients, four achieved a partial response (two confirmed and two unconfirmed) despite having previously experienced disease progression following platinum-based chemotherapy.Conclusions: Berzosertib plus cisplatin is well tolerated and shows preliminary clinical activity in patients with advanced solid tumours, warranting further evaluation in a Phase 2 setting.Clinical Trials Identifier: NCT02157792.Keywords
Funding Information
- Merck KGaA (N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A)
- Vertex Pharmaceuticals (N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A)
This publication has 24 references indexed in Scilit:
- Anti‐tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cellsInternational Journal of Cancer, 2016
- Abstract 3717: Defining optimal dose schedules for ATR inhibitors in combination with DNA damaging drugs: Informing clinical studies of VX-970, the first-in-class ATR inhibitorCancer Research, 2016
- The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancerin vivoOncotarget, 2015
- Drug Resistance in Cancer: An OverviewCancers, 2014
- Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970Oncotarget, 2014
- Causes and consequences of replication stressNature Cell Biology, 2013
- Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATRNature Chemical Biology, 2011
- Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic BiomarkersClinical Cancer Research, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Molecular mechanisms of resistance and toxicity associated with platinating agentsCancer Treatment Reviews, 2007